INTRODUCTION {#s0}
============

Lactic acid bacteria (LAB), alongside other food-based platforms, have been utilized since the 1990s for therapeutic heterologous gene expression ([@B1]). The ability of LAB to elicit an immune response against expressed foreign antigens has led to their use as potential candidates as mucosal vaccine vectors. As vaccine vectors, they offer several attractive advantages: simple, noninvasive administration (usually oral or intranasal), the acceptance and maintenance of genetic modifications, low cost, and high safety levels. LAB tend to elicit minimal immune responses against themselves, instead inducing high levels of systemic and mucosal antibodies against the expressed foreign antigen following uptake via the mucosal immune system ([@B2]).

LAB for use as vaccine vectors generally include Streptococcus gordonii, Lactococcus lactis, or multiple *Lactobacillus* species. S. gordonii has generally fallen out of use, with a few exceptions ([@B3]). L. lactis and *Lactobacillus* spp. have continued to grow in use, with the number of publications continuing to increase. Several excellent reviews of L. lactis vaccines have been published ([@B4][@B5][@B6]), as well as articles describing how to generate these recombinant bacteria ([@B7]). Because of the large number of recent articles detailing lactobacilli as vaccine vectors, this review focuses on those publications and on the resulting immune responses generated *in vivo*.

Briefly, this review is divided into sections corresponding to the pathogen/disease of interest (virus, bacterium). Pathogen species or families that have been investigated in multiple studies (i.e., human immunodeficiency virus \[HIV\], Escherichia coli) are then highlighted, focusing on the immune responses resulting from *Lactobacillus* vaccination. This review covers only research involving *Lactobacillus* strains with heterologous gene expression. Studies conducted with unmodified *Lactobacillus* used either as an adjuvant or for intrinsic antibacterial or antiviral properties are excluded ([@B8], [@B9]). The text of this review focuses on *in vivo* immune responses and on selected *in vitro* studies with a significant immune component, with [Table 1](#tab1){ref-type="table"} highlighting viral antigens and [Table 2](#tab2){ref-type="table"} highlighting bacterial antigens.

###### 

Primary articles describing studies that utilized *Lactobacillus* to express viral antigens[^a^](#ngtab1.1){ref-type="table-fn"}

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Pathogen           *Lactobacillus*\         Antigen(s)\     Expression          Result(s)                                     Intended\   Reference
                     species                  expressed                                                                         host(s)     
  ------------------ ------------------------ --------------- ------------------- --------------------------------------------- ----------- -----------
  CAV                L. acidophilus           VP1             Surface             Serum Ab, T cell response                     Poultry     [@B93]

  CSFV               L. plantarum             E2              Surface             Serum IgG, mucosal IgA, T cell response       Swine       [@B62]

  CSFV               L. casei                 CTL 290         Secreted            Serum IgG, mucosal IgA, T cell response,\     Swine       [@B60]
                                                                                  challenge                                                 

  CSFV               L. casei                 CTL 290         Unknown             Serum IgG, T cell response, challenge         Swine       [@B61]

  CSFV               L. casei                 CTL 290         Secreted            Serum IgG, mucosal IgA                        Swine       [@B94]

  CyHV-3             L. plantarum             ORF81           Surface             IgM, challenge                                Fish        [@B59]

  FMDV               L. casei, L. plantarum   VP1             Intracellular       Serum Ab, mucosal IgA                         Human       [@B95]

  FMDV               L. acidophilus           VP1             Unknown             Serum IgG, T cell response                    Animal      [@B66]

  GPV                L. plantarum             VP2             Unknown             Mucosal sIgA, TNF-α, IFN-γ, T cell response   Poultry     [@B96]

  HDV                L. casei, L. plantarum   HDVag           Intracellular       Serum Ab, mucosal IgA                         Human       [@B95]

  HIV                L. jensenii              scFv m9, dAb\   Secreted            Stability                                     Human       [@B19]
                                              m36, m36.4                                                                                    

  HIV                L. acidophilus           MPER            Surface             Serum IgG, mucosal IgA, mucosal IgG           Human       [@B13]

  HIV                L. plantarum             Gag             Surface             *In vitro* T cell line chemotaxis             Human       [@B14]

  HIV                L. jensenii              CV-N            Secreted            Safety, toxicity                              Human       [@B17]

  HIV                L. acidophilus           Gag             Surface             Mucosal IgA                                   Human       [@B12]

  HIV                L. jensenii              CV-N            Secreted            Challenge                                     Human       [@B16]

  HIV                L. fermentum             Gp41            Surface             Stability                                     Human       [@B97]

  HIV                L. jensenii              CV-N            Secreted            Safety, toxicity                              Human       [@B18]

  HPV                L. casei                 E7              Unknown             T cell response                               Human       [@B98]

  HPV                L. casei                 L2              Surface             Serum IgG, mucosal IgG, mucosal IgA,\         Human       [@B27]
                                                                                  challenge                                                 

  HPV                L. casei                 E7              Surface             CTL response, challenge                       Human       [@B29]

  HPV                L. casei                 E6              Surface             Serum IgG, mucosal IgA, challenge,\           Human       [@B26]
                                                                                  cross-neutralization                                      

  HPV                L. plantarum             E7              Surface             Serum IgG, challenge                          Human       [@B30]

  HPV                L. casei                 E7              Surface             Serum IgG, mucosal IgA, challenge             Human       [@B25]

  HPV                L. casei                 E7              Surface             T cell response                               Human       [@B28]

  HPV                Unknown                  E7              Surface             Unknown                                       Human       [@B99]

  HPV                L. casei                 L1, VLP         Intracellular       Serum IgG                                     Human       [@B23]

  HPV                L. plantarum             E7              Surface             Stability                                     Human       [@B100]

  HPV                L. casei                 E7              Unknown             Increased cervical lymphocytes, decreased\    Human       [@B31]
                                                                                  pathology                                                 

  IBDV               L. casei                 VP2             Unknown             Serum IgG, mucosal IgA, challenge survival    Poultry     [@B101]

  IBV                L. salivarius            EpiC            Surface             Stability, toxicity                           Poultry     [@B102]

  IBV                L. salivarius            EpiC            Secreted            Stability                                     Poultry     [@B102]

  Influenza virus    L. casei                 NP              Unknown             Stability                                     Human       [@B103]

  Influenza virus    L. casei                 sM2, HA2        Surface             Serum IgG, mucosal IgA, challenge             Human,\     [@B37]
                                                                                                                                animal      

  Influenza virus    L. casei                 sM2             Surface             Serum IgG, mucosal IgA, T cell response,\     Human       [@B36]
                                                                                  challenge                                                 

  Influenza virus    L. delbrueckii           HA              Unknown             Serum IgG, mucosal IgA, challenge             Poultry     [@B35]

  Influenza virus    L. casei                 NP              Unknown             Stability                                     Human       [@B104]

  Influenza virus\   L. plantarum             M2e             Unknown             Mucosal IgA, T cell response, challenge       Human,\     [@B105]
  (H1N1)                                                                                                                        swine       

  Influenza virus\   L. acidophilus,\         HA              Unknown             Serum IgG, mucosal IgA                        Human,\     [@B34]
  (H5N1)             L. delbrueckii                                                                                             poultry     

  Influenza virus\   L. plantarum             HA              Unknown             Serum IgG, mucosal IgA, T cell response,\     Poultry     [@B33]
  (H9N2)                                                                          challenge                                                 

  Influenza virus\   L. plantarum             NP, M1          Unknown             Serum IgG, mucosal sIgA, T cell response,\    Poultry     [@B106]
  (H9N2)                                                                          challenge                                                 

  Influenza virus\   L. plantarum             HA              Unknown             Serum IgG, mucosal IgA, T cell response,\     Poultry     [@B32]
  (H9N2)                                                                          challenge                                                 

  Influenza virus\   L. plantarum             NP, M1          Unknown             Mucosal IgA, T cell response, challenge       Poultry     [@B107]
  (H9N2)                                                                                                                                    

  Influenza virus\   L. casei                 NS1             Surface             Stability                                     Human\      [@B108]
  (H5N1)                                                                                                                        Poultry     

  IPNV               L. casei                 VP2, VP3        Surface, secreted   Serum IgM, challenge protection               Fish        [@B58]

  IPNV               L. casei                 VP2             Surface, secreted   Serum IgM, challenge                          Fish        [@B57]

  NDV                L. plantarum             HN              Unknown             Serum IgA, mucosal IgA, T cell response,\     Poultry     [@B65]
                                                                                  challenge                                                 

  Norwalk virus      L. casei                 VP60            Intracellular       Stability                                     Human       [@B109]

  PEDV               L. casei                 COE             Surface             Serum IgG, mucosal IgA, T cell response,\     Swine       [@B45]
                                                                                  \> neutralization                                         

  PEDV               L. casei                 S1, N           Surface, secreted   Serum IgG, mucosal IgA                        Swine       [@B44]

  PEDV               L. casei                 N               Surface             Serum IgG, mucosal IgA                        Swine       [@B110]

  PEDV               L. casei                 N               Surface             Serum IgG, mucosal IgA                        Swine       [@B46]

  Porcine RV         L. casei                 VP4             Surface             Serum IgG, mucosal IgA, neutralization        Swine       [@B53]

  Porcine RV         L. acidophilus           VP7             Unknown             Mucosal IgA, challenge                        Swine       [@B111]

  Porcine RV         L. casei                 VP4             Unknown             Serum IgG, mucosal sIgA, neut. Ab             Swine       [@B112]

  PPV                L. casei                 VP2             Secreted            Serum IgG, mucosal IgA, T cell response,\     Swine       [@B60]
                                                                                  challenge                                                 

  PPV                L. casei                 VP2             Surface, secreted   Serum IgG, mucosal IgA                        Swine       [@B64]

  PPV                L. casei                 VP2             Secreted            Serum IgG, mucosal IgA                        Swine       [@B94]

  PPV                L. casei                 VP2             Surface             Serum IgG, mucosal IgA                        Swine       [@B63]

  RV                 L. rhamnosus             ARP1            Surface             Challenge                                     Human       [@B54]

  RV                 L. paracasei             ARP1--ARP3      Surface, secreted   Stability                                     Human       [@B113]

  RV                 L. rhamnosus             IgGb, IgGd      Surface             Challenge                                     Human       [@B55]

  SARS-CoV           L. casei                 SA, SB          Surface             Serum IgG, mucosal IgA                        Human       [@B42]

  SVCV               L. plantarum             GP              Surface             IgM, challenge                                Fish        [@B59]

  TGEV               L. casei                 D               Surface             Serum IgG, mucosal IgA, T cell response,\     Swine       [@B47]
                                                                                  challenge                                                 

  TGEV               L. casei                 MDP             Surface             Serum IgG, mucosal IgA, T cell response,\     Swine       [@B41]
                                                                                  neutralization                                            

  TGEV               L. pentosus              6D              Surface, secreted   Serum IgG, mucosal IgA                        Swine       [@B40]

  TGEV               L. casei                 S               Secreted            Serum IgG, mucosal IgA                        Swine       [@B39]
  -----------------------------------------------------------------------------------------------------------------------------------------------------

CAV, chicken anemia virus; CyHV-3, cyprinid herpesvirus 3; FMDV, foot-and-mouth disease virus; GPV, goose parvovirus; HDV, hepatitis D virus; IBDV, infectious bursal disease virus; IBV, infectious bronchitis virus; NDV, Newcastle disease virus; Porcine RV, porcine rotavirus; PPV, porcine parvovirus; SVCV, spring viremia of carp virus; Ab, antibody; neut. Ab, neutralizing antibody; sIgA, secretory immunoglobulin G; scFv, single chain variable fragment.

###### 

Primary articles describing studies that utilized *Lactobacillus* to express bacterial antigens[^a^](#ngtab2.1){ref-type="table-fn"}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Pathogen                      *Lactobacillus*\   Antigen(s)\      Expression     Result(s)                                       Intended\     Reference
                                species            expressed                                                                       host(s)       
  ----------------------------- ------------------ ---------------- -------------- ----------------------------------------------- ------------- -----------
  Bacillus anthracis            L. gasseri         PA               Unknown        Serum IgG, mucosal IgA, T cell response         Human,\       [@B71]
                                                                                                                                   animal        

  Bacillus anthracis            L. gasseri         PA               Unknown        Neutr. Ab, T cell response, challenge           Human         [@B70]

  Bacillus anthracis            L. acidophilus     PA               Surface        Neutr. Ab, mucosal IgA, challenge               Human         [@B69]

  Bacillus anthracis            L. casei           PA               Surface,\      Serum IgG                                       Human         [@B68]
                                                                    intracell.,\                                                                 
                                                                    secreted                                                                     

  Bacillus anthracis            L. acidophilus     PA               Surface        Stability                                       Human         [@B114]

  Borrelia burgdorferi          L. plantarum       OspA             Surface        Serum IgG, mucosal IgA                          Human         [@B83]

  Borrelia burgdorferi          L. plantarum       OspA             Unknown        Serum IgG, mucosal IgA, challenge               Human         [@B82]

  Bordetella pertussis          L. casei           FHA              Intracell.     Serum IgG                                       Human         [@B115]

  Clostridium botulinum         L. acidophilus     BoNT/A-Hc        Surface        Stability                                       Human         [@B114]

  Clostridium perfringens       L. casei           ε-Toxoid         Surface        Serum IgG, serum IgA, intestinal IgA, IFN-γ,\   Human,\       [@B86]
                                                                                   challenge                                       animal        

  Clostridium perfringens       L. casei           α-, β1-, β2-,\   Unknown        Serum IgG, fecal IgA, nasal IgA, IFN-γ/IL-4,\   Human,\       [@B116]
                                                   ε-toxoids                       T cell response, challenge                      animal        

  Clostridium perfringens       L. casei           β-Toxoid         Surface,\      Serum IgG, serum IgA, intestinal IgA, IFN-γ,\   Human,\       [@B117]
                                                                    intracell.     challenge                                       animal        

  Clostridium perfringens       L. casei           α-Toxoid         Surface        Serum IgG, mucosal IgA, challenge               Human,\       [@B118]
                                                                                                                                   animal        

  Chlamydia psittaci            L. fermentum       OmpA             Surface        Stability                                       Animal        [@B97]

  Clostridium tetani            L. casei           TTFC             Surface,\      Serum IgG                                       Human         [@B119]
                                                                    intracell.,\                                                                 
                                                                    secreted                                                                     

  Clostridium tetani            L. plantarum       TTFC             Intracell.     Serum IgG, mucosal IgA                          Human         [@B120]

  Clostridium tetani            L. plantarum       TTFC             Intracell.     Serum IgG                                       Human         [@B121]

  Clostridium tetani            L. johnsonii       TTFC             Surface        Serum IgG, mucosal IgA                          Human         [@B122]

  Clostridium tetani            L. plantarum       TTFC             Intracell.,\   Serum IgG, mucosal IgA                          Human         [@B123]
                                                                    secreted,\                                                                   
                                                                    surface                                                                      

  Clostridium tetani            L. plantarum       TTFC             Intracell.     Serum IgG, mucosal IgA, T cell response,\       Human         [@B124]
                                                                                   challenge                                                     

  Clostridium tetani            L. plantarum,\     TTFC             Intracell.,\   Serum IgG, mucosal IgA, T cell response         Human         [@B125]
                                L. casei                            surface                                                                      

  Chlamydia trachomatis         L. plantarum,\     VD4              Surface        Stability                                       Human         [@B126]
                                L. fermentum                                                                                                     

  Chlamydia trachomatis         L. plantarum       Hirep2           Surface        Serum IgG, serum IgA, mucosal IgA, IFN-γ        Human         [@B90]

  Escherichia coli (EHEC\       L. acidophilus     EspA,\           Secreted       Serum IgG, mucosal sIgA, IFN-γ, IL-4, IL-10,\   Human         [@B127]
  O157:H7)                                         Tir                             challenge                                                     

  Escherichia coli (EPEC)       L. casei           β-Intimin        Unknown        Serum IgG, mucosal IgM, challenge               Human         [@B77]

  Escherichia coli (ETEC)       L. casei           K88              Unknown        Serum IgG, mucosal sIgA, challenge              Human         [@B128]

  Escherichia coli (ETEC)       L. casei           FaeG             Secreted       Stability                                       Human         [@B129]

  Escherichia coli (ETEC)       L. casei           FP               Secreted       Stability                                       Human         [@B129]

  Escherichia coli (ETEC)       L. casei           F1               Surface        Serum IgG, mucosal IgA, challenge               Swine,\       [@B75]
                                                                                                                                   ruminants,\   
                                                                                                                                   human         

  Escherichia coli (ETEC)       L. casei           K88, K99         Surface        Serum IgG, mucosal IgA, T cell response         Swine,\       [@B74]
                                                                                                                                   ruminants,\   
                                                                                                                                   human         

  Escherichia coli (ETEC)       L. casei           K99              Surface        Serum IgG, mucosal IgA                          Swine,\       [@B73]
                                                                                                                                   ruminants,\   
                                                                                                                                   human         

  Escherichia coli (ETEC)       L. casei           F41              Surface        Serum IgG, mucosal IgA, T cell response         Swine,\       [@B72]
                                                                                                                                   ruminants,\   
                                                                                                                                   human         

  Escherichia coli (ETEC)       L. reuteri         ST, LT(B)        Secreted       Serum IgG, mucosal IgA, challenge\              Swine,\       [@B76]
                                                                                   protection                                      ruminants,\   
                                                                                                                                   human         

  Escherichia coli (ETEC)       L. acidophilus     K99              Surface        *In vitro* inhibition of pathogen adhesion      Swine,\       [@B130]
                                                                                                                                   ruminants,\   
                                                                                                                                   human         

  Escherichia coli (ETEC)       L. plantarum       Fimbrial\        Unknown        Serum IgG, intestinal IgA, challenge            Swine,\       [@B131]
                                                   adhesin\                                                                        ruminant,\    
                                                   (FaeG)                                                                          human         

  Escherichia coli (UPEC)       L. reuteri         PapG             Surface        Stability                                       Human         [@B132]

  Helicobacter pylori           L. acidophilus     Hp0410           Unknown        Serum IgG, mucosal IgA, challenge               Human         [@B85]

  Helicobacter pylori           L. acidophilus     Hp0410           Surface        Stability                                       Human         [@B133]

  Helicobacter pylori           L. plantarum       UreB             Unknown        Serum IgG, serum IgA, challenge                 Human         [@B134]

  Mycobacterium avium\          L. salivarius      MMP              Surface        Stability                                       Ruminant      [@B135]
  (MAP)                                                                                                                                          

  Mycobacterium avium\          L. salivarius      ptD              Intracell.     Stability                                       Ruminant      [@B136]
  (MAP)                                                                                                                                          

  Mycobacterium tuberculosis    L. plantarum       Ag85B,\          Surface        Mucosal IgA, T cell response                    Human         [@B137]
                                                   ESAT-6                                                                                        

  Salmonella enterica (SE)      L. casei           FliC, SipC       Surface        Serum IgG, T cell response                      Human,\       [@B138]
                                                                                                                                   animal        

  Salmonella enterica (SE)      L. casei           FliC             Surface        Challenge                                       Human         [@B139]

  Streptococcus mutans          L. zeae            scFv             Surface,\      Challenge                                       Human         [@B140]
                                                                    secreted                                                                     

  Streptococcus pneumoniae      L. casei           PspC             Surface,\      Mucosal IgA, challenge                          Human         [@B141]
                                                                    intracell.                                                                   

  Streptococcus pneumoniae      L. casei           PspA, PspC       Surface        Serum IgG, mucosal IgA                          Human         [@B81]

  Streptococcus pneumoniae      L. casei           PspA             Surface        Serum IgG, challenge                            Human         [@B80]

  Streptococcus pneumoniae      L. casei,\         PspA             Surface        Serum IgG, mucosal IgA, challenge               Human         [@B79]
                                L. plantarum,\                                                                                                   
                                L. helveticus                                                                                                    

  Streptococcus pneumoniae      L. casei           PsaA, PspA′1,\   Intracell.,\   Stability                                       Human         [@B142]
                                                   PspA′3           secreted                                                                     

  Streptococcus pyogenes        L. gasseri         CRR6             Unknown        Serum IgG, mucosal IgA, challenge               Human         [@B143]

  Streptococcus pyogenes        *L. sake*,\        M6               Secreted,\     Stability                                       Human         [@B144]
                                L. fermentum                        surface                                                                      

  V. cholerae                   L. casei,\         CTB              Intracell.,\   Serum IgG                                       Human         [@B145]
                                L. reuteri                          secreted                                                                     

  Vibrio parahaemolyticus       L. rhamnosus       MAM-7            Unknown        MAM-7 expression (reduced *Lactobacillus*\      Human         [@B146]
                                                                                   ability to inhibit pathogen)                                  

  Vibrio parahaemolyticus       L. rhamnosus       MAM-7            Unknown        Stability                                       Human         [@B146]

  Yersinia pestis               L. plantarum       LcrV             Surface        Serum IgG, mucosal IgA, T cell response         Human         [@B84]

  Yersinia pseudotuberculosis   L. plantarum       D1-D5, D4-D5     Surface        Stability                                       Human         [@B147]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

FHA, filamentous hemagglutinin adhesin; BoNT, clostridial botulinum neurotoxin; TTFC, tetanus toxin fragment C; FP, fusion protein; MMP, mucous membrane pemphigoid; intracell., intracellular; Neutr. Ab, neutralizing antibody.

VIRUSES {#s1}
=======

Human immunodeficiency virus. {#s1.1}
-----------------------------

Human immunodeficiency virus type 1 (HIV-1) has been relegated to the status of being a treatable chronic disease, and yet infection rates are unacceptably high ([@B10]). An effective HIV vaccine is still elusive via traditional methods, with statistical significance limitations plaguing the only modestly successful clinical trial ([@B11]). Utilizing lactobacilli as mucosal vaccine vectors can provide an enhanced immune response at the typical mucosal sites of infection. Several studies have looked at lactobacilli expressing HIV antigens, thus targeting the virus at the most common site of infection, namely, the mucosa. Our laboratory has shown that expressing additional secreted molecules as adjuvants (interleukin 1β \[IL-1β\], *Salmonella* flagellin C) can significantly improve the mucosal (IgA) and systemic (serum IgG) immune responses against HIV proteins (MPER, Gag) in orally dosed mice ([@B12], [@B13]). Kuczkowska et al. have shown *in vitro* evidence of T cell recruitment using an L. plantarum strain expressing a fusion protein of CCL3/HIV Gag ([@B14]). No challenge studies in monkeys or humans have been performed to determine the efficacy of the immune response.

An alternative preventative measure against HIV is the use of prophylactic topical microbicides, which can be effective in high-risk groups ([@B15]). By incorporating microbicide expression into lactobacilli, mucosal sites can be colonized and continuously protected, reducing cost and the need for strict adherence. In two separate studies, Lagenaur et al. utilized a vagina-associated L. jensenii strain secreting cyanovirin-N, a promising microbicide with high affinity for HIV envelope glycoproteins. This application was safe in rhesus macaques and afforded protection against simian-human immunodeficiency virus (SHIV) challenge ([@B16][@B17][@B18]). That group also used lactobacilli for secretion of broadly neutralizing antibody fragments to protect the vaginal mucosa, though the work was still performed *in vitro* ([@B19]). Human trials are under way.

Human papillomavirus. {#s1.2}
---------------------

The association between human papillomavirus (HPV) and various cancers, particularly cervical cancer, is well known ([@B20]). Because of this association, HPV proteins are usually expressed on the surface cervical cancer cells. This allows an immune response that not only targets potentially infectious virus but can also destroy infected, cancerous cells. There are currently two FDA-approved vaccines against the most common strains of HPV (vaccines Gardasil and Cervarix). Both generate protective immune responses via spontaneous virus-like particle (VLP) formation of the HPV L1 capsid protein ([@B21]). While these vaccines provide excellent protection and represent potential cancer therapies, the cost can prove prohibitive even in the United States ([@B22]). Only one research group has utilized *Lactobacillus* to generate VLPs using the L1 protein, resulting in serum IgG expression following subcutaneous injection in BALB/c mice ([@B23]). All other research groups have utilized surface expression of HPV proteins, either minor capsid protein L2 or the early oncoproteins E6 and E7, which are directly responsible for unregulated cellular replication ([@B24]). In an extensive set of early experiments, Poo et al. utilized an E7-expressing L. casei strain, observing serum IgG along with intestinal and vaginal IgA in orally immunized C57BL/6 mice. They also observed E7-specific gamma interferon (IFN-γ)-secreting cells in the vagina and spleen, as well as a therapeutic reduction in tumor size and increased animal survival following TC-1 tumor cell challenge ([@B25]). A similar study using E6 had similar results ([@B26]). Poo et al. later targeted the L2 protein in BALB/c mice, observing serum IgG, mucosal IgG and IgA, and cross-neutralization with related viruses ([@B27]). Using L. casei administered to C57BL/6, Adachi et al. observed increased levels of E7-specific T cells in the gut, as well as granzyme-B production. Mucosal lymphocytes were found to be capable of TC-1 cell lysis, a result which was also repeated by another research group ([@B28], [@B29]). Interestingly, oral administration improved the response in comparison to the results seen with subcutaneous or intramuscular administration ([@B28]). Another research group utilized L. plantarum expressing E7, with similar antibody and antitumor results, though they checked only for antibodies in the serum and not in the mucosa ([@B30]). Because of the observed therapeutic effect seen in several studies, a human trial using cervical cancer (cervical intraepithelial neoplasia grade 3 \[CIN3\]) patients was conducted and demonstrated the presence of E7-specific lymphocytes in cervical tissues but not in blood, with the majority of patient tumor pathologies being downgraded ([@B31]). Taken together, the data show great promise and potential for the development of anti-HPV *Lactobacillus* vaccines to meet an important public health need.

Influenza virus. {#s1.3}
----------------

The unpredictability of the availability of future influenza virus strains, as well as supply problems stemming from slow growth methods (egg and cell based), means that anti-influenza *Lactobacillus* vaccines could fill a need, particularly for treatment of infections by highly pathogenic strains such as H5N1. Shi et al. showed that oral administration of an L. plantarum strain expressing H9N2 hemagglutinin (HA) induced fecal IgA, bronchiolar IgA, and serum IgG. B cell levels in secondary lymphoid organs were increased, and CD8^+^ T cell proliferation and IFN-γ secretion were greatly improved relative to the levels seen with a typical influenza vaccine. Most importantly, vaccinated mice survived lethal challenge ([@B32]). These results were seen again in assays using dendritic cell-targeting peptide (DC-pep) adjuvant, which showed improved immune responses and challenge survival in chickens ([@B33]). Similar antibody and T cell results were observed in targeting H5N1 hemagglutinin (HA~1~) in BALB/c mice ([@B34]) and chickens ([@B35]). Other influenza virus proteins have also been targeted. Chowdhury et al. granted BALB/c mice protection (via oral or intranasal administration) from multiple lethal challenge strains and showed that inclusion of cholera toxin subunit A1 (CTA1) significantly improved antibody levels and protection ([@B36]). A follow-up study showed that antibody levels and IFN-γ secretion and proliferation, as well as protection against lethal challenge, lasted 7 months postvaccination ([@B37]).

Coronavirus. {#s1.4}
------------

Until the recent outbreaks of severe acute respiratory syndrome (SARS) (2003) and Middle East respiratory syndrome (MERS) (2014/2015), coronavirus (CoV) morbidity and mortality were generally worse for domesticated animals rather than for humans, particularly within porcine and poultry farms. Coronaviruses usually infect via the gastrointestinal tract in livestock and the respiratory tract in birds and humans, causing devastating economic losses and dangerous morbidities in the young, old, and immunocompromised ([@B38]). The first coronavirus addressed using lactobacilli was transmissible gastroenteritis coronavirus (TGEV), which affects swine, particularly piglets. Several spike protein epitopes have been targeted (S, 6D), resulting in induction of serum IgG and mucosal IgA in mice ([@B39], [@B40]). More recently, the muramyl dipeptide (MDP) protein was targeted, utilizing tuftsin as an adjuvant, and the results showed improved antibody and T cell responses in BALB/c mice ([@B41]). The only human coronavirus addressed was SARS-CoV, with induction of serum IgG and mucosal IgA against spike proteins (SA, SB) observed in C57BL/6 mice ([@B42]). Porcine epidemic diarrhea virus (PEDV) is another coronavirus that primarily affects piglets, resulting in large economic losses ([@B43]). In a thorough set of experiments, Liu et al. showed that, by targeting both the spike protein (S1) and nucleocapsid (N) via surface expression (rather than via secretion), levels of anti-S1 and anti-N antibodies were significantly increased, even in atypically studied secretions such as ophthalmic and nasal secretions ([@B44]). Interestingly, they observed a synergy against the spike protein, but not against the nucleocapsid, in mice vaccinated against both proteins.

To improve the immune response against TGEV's core neutralizing epitope (COE), Ge et al. fused the COE with E. coli enterotoxin B (LTB), with results which showed some statistical significance, particularly with respect to splenocyte IFN-γ and IL-4 secretion ([@B45]). In perhaps the most directly useful study, Hou et al. observed the increased presence of anti-nucleocapsid antibodies in the milk and colostrum of nursing sows, correlating with increased anti-N serum IgG levels in suckling piglets ([@B46]). A recent set of experiments by Jiang et al. delved deeper into the immune response generated by L. casei, highlighted by strong mucosa-dependent protection from infection, stimulation of the IL-17 pathway, and an imbalance between the Th1 and Th2 responses, as indicated by variations in numbers of CD4^+^ T cells containing either intracellular IFN-γ or IL-4 ([@B47]). Interestingly, some *Lactobacillus* species have been shown to downregulate IL-17 responses ([@B48]), but this simply points to the delicate balance that Th17 cells must strike between pathogen-stimulated inflammation and the potential damage of errant autoimmune inflammation ([@B49]). It is clear that homeostasis with respect to inflammation, immunity, lactobacilli, and Th17 cells is a complex subject and is dependent on a number of factors, including host genetics, pathogen, *Lactobacillus* strain, and adjuvants.

Rotavirus. {#s1.5}
----------

Diarrheal disease is the second leading cause of death in children under the age of 5 worldwide, with rotavirus responsible for 40% of hospitalizations due to diarrheal illness ([@B50]). It is estimated that rotavirus killed approximately 215,000 children in 2013. The World Health Organization recommends inclusion of a rotavirus vaccine in all global vaccination protocols, and there are currently two modified live vaccines licensed worldwide ([@B51]). The global implementation is ongoing, but in countries where data are available, vaccination has resulted in a 33% reduction in hospitalization due to rotavirus morbidities. Unfortunately, both vaccines have limited (50% to 60%) efficacy in developing countries and are associated with a low-level risk of intussusception ([@B52]). A recombinant *Lactobacillus*-based vaccine could address the need for a subunit rotavirus vaccine that provides the benefits of a probiotic and the appropriate safety profile for use in neonates and infants. Two main avenues of lactobacillus-based rotavirus protection have been attempted in mice. The first avenue used typical oral vaccination with L. casei, inducing mucosal IgA and neutralizing serum IgG against porcine Rotavirus major protective antigen (PA) VP4 in mice ([@B53]). The second used antibody fragments to confer protection. Álvarez et al. expressed a protective anti-rotavirus llama antibody fragment on the surface of L. rhamnosus, protecting against diarrhea in a mouse pup model ([@B54]). Another group adapted the use of anti-rotavirus hyperimmune bovine colostrum (HBC) in the same model system, expressing an anti-HBC protein from *Streptococcus*, which binds HBC antibodies, thus conferring protection when orally dosed ([@B55]).

Fish-related viruses. {#s1.6}
---------------------

Aquaculture is an important food supply paradigm, and with it comes the typical pathogen problems that large-scale animal farms encounter. Vaccination against fish pathogens can be performed by intraperitoneal administration (which can be cost-prohibitive), by immersion, or orally via feed, with the latter two options suffering from a lack of vaccine persistence in water and from the particularly strong mucosal tolerance observed in fish. For a comprehensive summary of vaccination attempts in fish, see the excellent review by Embregts and Forlenza ([@B56]). Lactobacillus vaccine vectors can provide an effective and easily administered system for pisciculture. The first set of studies targeted infectious pancreatic necrosis virus (IPNV), a birnavirus that afflicts rainbow trout. Direct oral administration with L. casei expressing portions of viral capsid generated significant serum IgM and afforded challenge protection in two studies by the same group ([@B57], [@B58]). Two viruses that primarily affect carp, *Cyprinid herpesvirus 3* (Koi herpesvirus \[KHV\]) and Rhabdovirus carpio (spring viremia of carp virus \[SVCV\]), have also been studied. The two antigens (KHV ORF81 and SVCV glycoprotein) were expressed together in L. plantarum and dosed orally in carp and koi. The resulting serum IgM and challenge survival data were promising, particularly for a vaccine that offers dual protection ([@B59]). Further *Lactobacillus* studies must be conducted, looking in particular at cellular mucosal immunity in fish, as well as at the potential for multiple pathogens to be addressed with a single modified *Lactobacillus* vaccine.

Other viruses. {#s1.7}
--------------

In addition to the categories already addressed, a large and diverse number of viruses have been targeted using *Lactobacillus* vector systems. A few are highlighted here, with the rest detailed in [Table 1](#tab1){ref-type="table"}. Classical swine fever virus (CSFV), a flavivirus affecting pigs, has been tested in rabbits, mice, and pigs, with all tests resulting in production of serum and mucosal antibodies ([@B60], [@B61]). Importantly, addition of thymosin α-1, a T cell-stimulating peptide, was able to increase levels of IgG, IgA, IFN-γ, IL-2, and tumor necrosis factor alpha (TNF-α) in pigs ([@B62]). *Porcine parvovirus* has been studied in BALB/c mice and pigs, with excellent IgG and IgA responses, as well as challenge protection and virus neutralization ([@B60], [@B63], [@B64]). A recent study observed strong protective immune responses in chickens against *Newcastle disease virus*, a paramyxovirus primarily afflicting poultry, which were improved by the addition of DC-pep, which not only boosted mucosal and serum antibody levels but also increased levels of T helper cells in the spleen and peripheral blood versus the results seen with bacteria without DC-pep ([@B65]). Foot-and-mouth disease virus, a *Picornavirus* afflicting cloven-hooved animals, was investigated in a comprehensive dosing study that assessed anticapsid immune responses resulting from administration of recombinant L. acidophilus via the intramuscular, intraperitoneal, intranasal, or oral route. Of note, this vaccine strategy utilized the bacteria as a delivery vehicle for a capsid-expressing DNA vaccine plasmid, in contrast to utilization of expression of heterologous proteins by the bacteria. The resulting antibody responses were thus much higher via intramuscular and intraperitoneal administration than via mucosal delivery ([@B66]). As the ease of use and awareness of *Lactobacillus* expression systems and their abilities to induce excellent mucosal and systemic immune responses increase, the number and variety of pathogens addressed will likely increase in the future.

BACTERIA {#s2}
========

Bacillus anthracis. {#s2.1}
-------------------

Though infections are relatively rare, the prevalence of natural Bacillus anthracis in soil and its potential as a bioterrorist agent gives antianthrax vaccines some priority. Protective antigen (PA), the only antigen used in *Lactobacillus* vaccinations, is well studied and has been tested in other vaccine systems with various degrees of success ([@B67]). One of the earliest proof-of-concept *Lactobacillus* experiments involved dosing BALB/c mice with L. casei either orally or intranasally. That early study showed that the antibody responses against heterologous protein exceeded the antibody responses against the bacteria itself ([@B68]). Ten years later, Mohamadzadeh et al. combined an L. acidophilus or L. gasseri strain with DC-pep, resulting in neutralizing antibodies and challenge survival in A/J mice ([@B69], [@B70]). That same group later observed colonic DC activation, Th17 and regulatory T cell (Treg) upregulation, and upregulation of pattern recognition receptor genes with a single vaccine dose ([@B71]).

Escherichia coli. {#s2.2}
-----------------

Enteric Escherichia coli bacteria are a major cause of diarrheal morbidity and mortality, particularly for children in developing countries. The most common antigens targeted for E. coli vaccination are fimbrial proteins, which are bacterial adhesins that aid in host cell binding. Most experiments mentioned here, except one, have targeted enterotoxigenic E. coli (ETEC). A prolific group from China utilized several fimbrial protein antigens (F41, K99, K88) over several years and in several models (BALB/c, C57BL/6, BALB/c pups), all using L. casei. Among their many findings, an increase in levels of several subclasses of serum IgG (IgG1, IgG2a, IgG2b) followed oral dosing, along with increased IL-4 levels and a lesser increase of IFN-γ levels measured by CD4^+^ T cell enzyme-linked immunosorbent spot (ELISPOT) assays. Intestinal and bronchiolar IgA levels were increased, and challenge with standard ETEC resulted in protection of \>80% of mice challenged with a lethal dose ([@B72]). The studies were repeated using intranasal dosing, which resulted in decreased intestinal IgA levels but increased bronchiolar IgA levels compared to oral delivery ([@B73]). Dosing in C57BL/6 mice induced similar IgG and IgA responses, as well as T cell proliferation and challenge protection ([@B74]). Challenge protection was conferred to mouse pups born to orally or intranasally immunized dams ([@B75]). Wu and Chung targeted two enterotoxins (ST and LT-B), rather than fimbrial proteins, with a secreted green fluorescent protein (GFP)/enterotoxin fusion protein. Similar increases in IgG and IgA levels were observed as well as challenge protection in a patent mouse gut assay ([@B76]). Ferreira et al. were the only group to target enteropathogenic E. coli (EPEC) and attempted the only sublingual dosing regimen. Experiments using L. casei expressing a portion of bacterial β-intimin (a cell surface protein that aids in attachment to the host cell) resulted in serum IgG and fecal IgA responses, though, interestingly, oral dosing did not generate an IgG response. Splenocytes also secreted elevated levels of IL-6 and IFN-γ, though only the results from the sublingual vaccination were reported ([@B77]). While Ferreira et al. performed their studies in C57BL/6 mice, they used C3H/HePas mice as their challenge model, due to that strain's susceptibility to Citrobacter rodentium, a commonly used strain that shares some pathology with EPEC ([@B78]). Ferreira et al. observed an increase in survival time, though animals eventually succumbed to disease.

Streptococcus pneumoniae. {#s2.3}
-------------------------

Most *Lactobacillus* experiments involving Streptococcus pneumoniae have been performed by the Oliveira laboratory and have focused on pneumococcal surface proteins (either PspA or PspC), with immunity studies conducted in C57BL/6 mice. Early work noted significant increases in bronchiolar IgA but not IgG levels following intranasal administration, with some variations due to bacterial strain differences ([@B79]). Strategies to increase antigen expression resulted in increased IgG levels (IgA levels were not measured), with enhancement of multiple IgG subsets (IgG1, IgG2a, IgG2b, IgG3). Challenge survival was improved compared to that seen with controls inoculated with saline solution alone, but no differences from the results seen with animals immunized with bacteria expressing the empty vector plasmid were observed ([@B80]). Further experiments identified a propensity for responses involving IgG1 versus IgG2a, which, along with increased IFN-γ levels and low levels of IL-5, indicated Th1 polarization. The levels of IL-17 secretion and neutrophil recruitment in the lungs varied by route of administration, adding to the idea of the importance of the manner in which vaccines are administered and not just of their expression of antigens ([@B81]). A final set of experiments failed to induce significant levels of IgA prior to challenge, but the researchers noted that challenge with S. pneumoniae did induce a significant IgA response, which correlated with reduced bacterial loads.

Other bacteria. {#s2.4}
---------------

Very few of the large number of pathogenic bacterial species have been targeted with lactobacilli, and such studies have been reported in only a few research publications. A few are highlighted here, with the rest addressed in [Table 2](#tab2){ref-type="table"}. Borrelia burgdorferi, the causative agent of Lyme disease, was targeted with an L. plantarum system, resulting in 100% protection following a B. burgdorferi-infected tick challenge ([@B82]). Those authors also identified what has become an interesting theme with lactobacillus vaccinations, i.e., that of dual Th1 and Th2 induction. *In vitro* work with human cells resulted in Th1 and Th2 cytokine responses, and oral administration in C3H-HeJ mice resulted in induction of both IgG1 (Th2) and IgG2a (Th1) ([@B83]). The same authors also targeted Yersinia pestis with L. plantarum, observing once again both inflammatory (TNF-α, IL-12, IFN-γ, and IL-6) and anti-inflammatory (IL-10) cytokines, indicating stimulation of both Th1 and Th2 responses ([@B84]). Importantly, however, as with the previous experiment, those were human *ex vivo* cytokine studies whose results were not confirmed *in vivo*. A vaccine targeting Helicobacter pylori, a common cause of stomach ulcers, would be extremely beneficial. By targeting H. pylori adhesin Hp0410 with an L. acidophilus strain, Hongying et al. generated anti-adhesion serum IgG and intestinal IgA that reduced bacterial load and gastric inflammation following challenge ([@B85]). Antibodies against the ε-toxoid of Clostridium perfringens were identified in BALB/c mice following oral L. casei administration, and though the statistical significance of the antibody levels was unclear, the animals survived challenge ([@B86]).

CONCLUSIONS {#s3}
===========

In order to combat most pathogens at their main point of entry, next-generation vaccines must establish protective mucosal immunity ([@B87]). Lactic acid bacteria, particularly species of genus *Lactobacillus*, have shown great promise as mucosal vectors that are capable of driving both systemic and mucosal responses, especially in combination with adjuvants. The number of studies involving lactobacilli has steadily increased over the last 20 years, and as data accumulate, key concepts regarding the immune responses that these vectors elicit have emerged. Interestingly, coinduction of Th1 and Th2 cytokines points to the complexity of T cell subsets in the mucosa. A growing number of studies have suggested that T cell effector plasticity in the mucosa, especially in the gut, is the norm and that the gut must strike a balance between tolerance and inflammation ([@B88]). This appears to be one major factor arising from these *Lactobacillus* studies, since evidence of Th17 inflammation, as well as of Treg-based tolerance, points to a complex T cell response. In terms of mucosal vaccination, this reiterates the importance of maintaining a balanced and well-characterized approach to immunogenicity. More work must be done to identify the contributing immune pathways within the mucosa, especially the routes of bacterial uptake into immune inductive sites (M cells, DCs).

There are several major takeaways as development of LAB vaccine platforms continues. While the safety of LAB is an important strength, enhancing protective immunogenicity is a key challenge. Several studies have explored strategies to express adjuvants such as cytokines, pathogen-associated molecular patterns, toxins, and targeting molecules for M cells and DCs. A mechanistic understanding of each of these strategies is necessary to design the right combination of immunogens and adjuvants that will result in protection. The route of administration, while typically oral for LAB, can have an effect on the type of response elicited due to differences in mucosal inductive sites. The intrinsic differences between strains of lactobacilli, as well as the location of antigen expression (surface display, intracellular, secreted), can alter the resulting immune response, and the strains must therefore be properly selected for specific antigens ([@B89]). Boosting is also clearly a component of successful vaccination, and there is evidence that heterologous prime-boost strategies may improve, or at least alter, the resulting immune response ([@B90]). As always, the model system must be taken into consideration, especially in light of new evidence for mucosal immune differences between the two most common mouse models (BALB/c and C57BL/6) ([@B91]). On the basis of their safety and efficacy, as well as their overall cost, *Lactobacillus* vaccine vectors hold great promise as mucosal vaccines. It is anticipated that the use of clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 analysis will allow a more sophisticated approach to engineering vaccine candidates ([@B92]). Ultimately, it is critical for one of these candidates to successfully navigate the regulatory gauntlet and demonstrate efficacy in a target population.

[^1]: **Citation** LeCureux JS, Dean GA. 2018. *Lactobacillus* mucosal vaccine vectors: immune responses against bacterial and viral antigens. mSphere 3:e00061-18. <https://doi.org/10.1128/mSphere.00061-18>.
